Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials

Angiogenesis is an integral process in carcinogenesis, and molecular inhibitors of angiogenic factors are currently being tested as treatments for cancer. Sunitinib is an oral multitargeted tyrosine-kinase inhibitor that blocks activation through the stem cell-factor receptor (Kit) and platelet-deri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sungkyoung, Ding, Wenping, Zhang, Lian, Tian, Wei, Chen, Siyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026584/
https://www.ncbi.nlm.nih.gov/pubmed/24872713
http://dx.doi.org/10.2147/OTT.S61388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026584/
https://www.ncbi.nlm.nih.gov/pubmed/24872713
http://dx.doi.org/10.2147/OTT.S61388

Ejemplares similares